secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0000950170-24-090332
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track
--------------------------------------------------------------------------------

- Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.
- Cash, cash equivalents and marketable securities $261.0M as of June 30; runway into 2029.
- FA program DT-216P2 on track to start patient trials in 2025 after GLP studies complete.
- FECD program DT-168 to begin Phase 1 in healthy volunteers in 2024; 200-patient observational study ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024090332/0000950170-24-090332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024090332/dsgn-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-090332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer